Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the "L-group" histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the developme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell communication and signaling 2022-12, Vol.20 (1), p.195-195, Article 195
Hauptverfasser:	Gao, Xue-Min, Li, Jian, Cao, Xin-Xin
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino acids Autoimmune diseases Histiocytosis Histiocytosis, Langerhans-Cell - pathology Humans Inflammation Inflammatory myeloid malignancy Kinases Langerhans cell histiocytosis Langerhans cell histiocytosis (LCH) Ligands Malignancy MAP kinase MAP Kinase Signaling System MAPK pathway MEK inhibitors Microenvironments Mitogen-Activated Protein Kinases - metabolism Mutation Pathogenesis Patients Progenitor cells Protein kinase Proteins Proto-Oncogene Proteins B-raf - metabolism RAF inhibitors Review Signal Transduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the "L-group" histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are detectable in nearly all LCH lesions. However, the pathogenic roles of MAPK pathway activation in the development of histiocytosis are still elusive. This review will summarize research concerning the landscape and pathogenic roles of MAPK pathway mutations and related treatment opportunities in Langerhans cell histiocytosis. Video abstract.
ISSN:	1478-811X 1478-811X
DOI:	10.1186/s12964-022-00917-0